Moleculin Biotech Operating Expenses Growth & History (MBRX)
Moleculin Biotech's operating expenses was $25.1M for fiscal 2025.
View full Moleculin Biotech company overviewMoleculin Biotech annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $25.1M | −$1.5M | −5.77% |
| 2024 | 2024-12-31 | $26.6M | −$3.0M | −10.09% |
| 2023 | 2023-12-31 | $29.6M | −$1.0M | −3.29% |
| 2022 | 2022-12-31 | $30.6M | $7.7M | +33.40% |
| 2021 | 2021-12-31 | $23.0M | $3.2M | +16.34% |
| 2020 | 2020-12-31 | $19.7M | $2.2M | +12.66% |
| 2019 | 2019-12-31 | $17.5M | $2.5M | +16.63% |
| 2018 | 2018-12-31 | $15.0M | $6.4M | +73.64% |
| 2017 | 2017-12-31 | $8.7M | $4.8M | +122.84% |
| 2016 | 2016-12-31 | $3.9M | — | — |
Moleculin Biotech quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.6M | $1.8M | +32.19% |
| Q1 2026 | 2026-03-31 | $7.9M | $1.9M | +32.49% |
| Q4 2025 | 2025-12-31 | $7.5M | $890,000 | +13.40% |
| Q3 2025 | 2025-09-30 | $5.9M | −$1.2M | −17.22% |
| Q2 2025 | 2025-06-30 | $5.7M | −$465,000 | −7.52% |
| Q1 2025 | 2025-03-31 | $5.9M | −$734,000 | −10.99% |
| Q4 2024 | 2024-12-31 | $6.6M | −$2.3M | −25.51% |
| Q3 2024 | 2024-09-30 | $7.1M | $1.2M | +19.98% |
| Q2 2024 | 2024-06-30 | $6.2M | −$226,000 | −3.53% |
| Q1 2024 | 2024-03-31 | $6.7M | −$1.7M | −20.07% |
| Q4 2023 | 2023-12-31 | $8.9M | $1.9M | +26.55% |
| Q3 2023 | 2023-09-30 | $5.9M | −$3.1M | −34.53% |
| Q2 2023 | 2023-06-30 | $6.4M | −$1.0M | −13.76% |
| Q1 2023 | 2023-03-31 | $8.4M | $1.3M | +18.09% |
| Q4 2022 | 2022-12-31 | $7.0M | $1.8M | +35.38% |
| Q3 2022 | 2022-09-30 | $9.1M | $2.9M | +47.54% |
| Q2 2022 | 2022-06-30 | $7.4M | $1.9M | +34.75% |
| Q1 2022 | 2022-03-31 | $7.1M | $986,000 | +16.20% |
| Q4 2021 | 2021-12-31 | $5.2M | $1.7M | +48.96% |
| Q3 2021 | 2021-09-30 | $6.2M | $6,000 | +0.10% |
| Q2 2021 | 2021-06-30 | $5.5M | $483,000 | +9.59% |
| Q1 2021 | 2021-03-31 | $6.1M | $1.0M | +20.27% |
| Q4 2020 | 2020-12-31 | $3.5M | −$1.3M | −27.38% |
| Q3 2020 | 2020-09-30 | $6.2M | $1.6M | +36.45% |
| Q2 2020 | 2020-06-30 | $5.0M | $1.4M | +38.60% |
| Q1 2020 | 2020-03-31 | $5.1M | $491,000 | +10.74% |
| Q4 2019 | 2019-12-31 | $4.8M | $474,000 | +10.92% |
| Q3 2019 | 2019-09-30 | $4.5M | $1.9M | +73.99% |
| Q2 2019 | 2019-06-30 | $3.6M | −$1.8M | −33.46% |
| Q1 2019 | 2019-03-31 | $4.6M | $1.9M | +73.34% |
| Q4 2018 | 2018-12-31 | $4.3M | $945,000 | +27.84% |
| Q3 2018 | 2018-09-30 | $2.6M | $187,000 | +7.78% |
| Q2 2018 | 2018-06-30 | $5.5M | $4.1M | +313.48% |
| Q1 2018 | 2018-03-31 | $2.6M | $1.1M | +71.79% |
| Q4 2017 | 2017-12-31 | $3.4M | $2.0M | +139.69% |
| Q3 2017 | 2017-09-30 | $2.4M | $982,000 | +69.06% |
| Q2 2017 | 2017-06-30 | $1.3M | $596,000 | +82.32% |
| Q1 2017 | 2017-03-31 | $1.5M | $1.2M | +378.19% |
| Q4 2016 | 2016-12-31 | $1.4M | — | — |
| Q3 2016 · Sep 30 | 2016-09-30 | $1.4M | $1.2M | +538.38% |
| Q2 2016 | 2016-06-30 | $724,000 | — | — |
| Q1 2016 | 2016-03-31 | $321,000 | — | — |
| Q3 2016 · Sep 30 | 2015-09-30 | $222,753 | — | — |
Moleculin Biotech operating expenses trends
Over the last five fiscal years, Moleculin Biotech's operating expenses increased from $19.7M to $25.1M, a change of $5.4M. The latest reported quarter, Q2 2026, shows $7.6M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Moleculin Biotech source filings ↗